07X Stock Chart & Stats
€1.53
€0.02(1.59%)
At close: 4:00 PM EDT
€1.53
€0.02(1.59%)
Day’s Range― - ―
52-Week Range€0.88 - €4.61
Previous CloseN/A
Volume0.00
Average Volume (3M)102.00
Market Cap
€37.19M
Enterprise Value€51.06M
Total Cash (Recent Filing)€18.73M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 11, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding42,679,058
10 Day Avg. Volume30
30 Day Avg. Volume102
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-2.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.51Price Target Upside521.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Reported DebtThe absence of reported debt reduces refinancing and interest-rate exposure, preserving more flexibility than a similarly loss-making business with leverage. Although cash generation remains weak, avoiding debt service can help management direct available funding toward ongoing clinical development.
Neurodegenerative Disease PipelineA defined focus on Alzheimer’s and Parkinson’s disease gives Annovis a coherent development strategy within major neurodegenerative conditions. Continued clinical, regulatory, and research activity provides an established framework for advancing candidates and pursuing future commercial validation.
Improved Disclosure AccuracyCorrecting the proxy disclosure improves the accuracy of governance reporting and demonstrates responsiveness when an error is identified. This supports clearer communication with shareholders and regulators, an enduring benefit for oversight even though it does not change operating results.
Bears Say
No Reported RevenueThe absence of reported revenue across multiple annual periods and the latest trailing period indicates that the business has not yet demonstrated commercial traction. This leaves development spending unsupported by operating sales and makes future funding dependent on external capital or successful clinical progress.
Persistent And Worsening LossesPersistent operating losses, culminating in an unusually large trailing-period net loss, show that expenses continue to materially exceed business income. This weak profitability profile limits internal reinvestment capacity and increases the importance of successful development milestones or additional financing.
Escalating Cash BurnConsistently negative operating and free cash flow means the company is not self-funding its operations, while the sharper trailing-period burn raises the urgency of obtaining capital. Sustained cash consumption can constrain clinical execution and increase future financing and dilution pressure.
Annovis Bio News
07X FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was €0.88 and its highest was €4.61 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is €37.19M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Nov 11, 2026 which is in 21 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Aug 14, 2026. The company reported -€0.345 earnings per share for the quarter, beating the consensus estimate of -€0.391 by €0.046.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -0.26.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 42,679,058 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -€0.345 in its last earnings report, beating expectations of -€0.391. Following the earnings report the stock price went up 0.654%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in DE:07X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.51 (521.47% Upside)
€9.51 (521.47% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.75%
12-Months-Change
Fundamentals
Return on Equity
-685.96%
Trailing 12-Months
Asset Growth
2.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Annovis Bio
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
07X Stock 12 Month Forecast
Average Price Target
€9.51
▲(521.47% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―